TVM Capital, Fonds de solidarité FTQ help launch Esperas Pharma
TVM Capital Life Science and the Fonds de solidarité FTQ have made an investment to help launch Esperas Pharma Inc, a Montréal-based biopharmaceutical company focused on treatments for certain types of cancer, including triple negative breast cancer. The value of the investment was not disclosed. Esperas Pharma said the deal will help it develop a biopharmaceutical asset to clinical proof-of-concept. Last October, TVM Capital Life Science, a global venture capital firm with an office in Montréal, closed TVM Life Science Ventures VlI at US$201.6 million. The fund, which made the Esperas Pharma investment, was backed by Teralys Capital, Eli Lilly and Co, BDC Capital and Fondaction CSN, among others.
14 April 2015•7 mins read
